Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Cameron Cook: How Cost-Effective Is Evolocumab for Patients at High Cardiovascular Risk?
Aug 6, 2026, 17:38

Cameron Cook: How Cost-Effective Is Evolocumab for Patients at High Cardiovascular Risk?

Cameron Cook, Senior HEOR Health Economist, Olpasiran HEOR Global Product Lead at Amgen, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in medRxiv, adding:

”Pleased to share a new preprint I co-authored, now available on medRxiv:

‘Cost-effectiveness of Evolocumab in Patients at High Cardiovascular Risk Without a Previous Myocardial Infarction or Stroke’

Using a Markov state health-economic model informed by cardiovascular outcomes evidence, the study projected improved cardiovascular outcomes and quality-adjusted survival with evolocumab added to standard therapy, and at the direct-to-patient price, remained cost-effective (significantly below AHH/ACC thresholds) across the base case and all scenario analyses evaluated.

Grateful to all fellow co-authors for the collaboration.

This manuscript is a preprint and has not yet undergone peer review.”

Title: Cost-effectiveness of Evolocumab in Patients at High Cardiovascular Risk Without a Previous Myocardial Infarction or Stroke

Authors: Gregg C. Fonarow, Cameron Cook, Eduard Sidelnikov, Sushmitha Inguva, Ajay Bhatia, Guillermo Villa

Cameron Cook: How Cost-Effective Is Evolocumab for Patients at High Cardiovascular Risk?

Stay updated on all scientific advances with Hemostasis Today.

Ajay Bhatia Cameron Cook cardiovascular risk Eduard Sidelnikov Evolocumab Gregg C Fonarow Guillermo Villa Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Sushmitha Inguva
NewsFeed